Comparing two heart ablation methods for atrial fibrillation in first-time patients
Compares two ablation methods to treat atrial fibrillation in adults.
Plain-language title generated from the registry record
Registry title: Lesion Formation With Pulsed Field Versus Cryobaloon Ablation as Assessed by Cardiac Magnetic Resoncance
Key facts
- Where
- Barcelona, SpainSee the site
Where in Spain
- Hospital Clinic, University of BarcelonaBarcelona, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital Clinic of Barcelona
- Trial code
- NCT06220006
- Record updated
- 7 April 2026
- Original description
This randomised study will compare pulsed field ablation and cryoballoon ablation with respect to ablation lesion quality as assessed by late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) at 3 months post-ablation. Patients scheduled for first-time AF ablation will be randomised in a 2:1 fashion to receive PVI-only, either by pulsed field ablation (Farapulse Pulsed Field Ablation System, Boston Scientific) or cryoballoon ablation (Medtronic Cryoballoon Ablation System).Read full original descriptionShow less
Lesion Formation With Pulsed Field Versus Cryobaloon Ablation as Assessed by Cardiac Magnetic Resoncance
This randomised study will compare pulsed field ablation and cryoballoon ablation with respect to ablation lesion quality as assessed by late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) at 3 months post-ablation. Patients scheduled for first-time AF ablation will be randomised in a 2:1 fashion to receive PVI-only, either by pulsed field ablation (Farapulse Pulsed Field Ablation System, Boston Scientific) or cryoballoon ablation (Medtronic Cryoballoon Ablation System).
Inclusion: Patients scheduled for first-time atrial fibrillation catheter ablation.
Exclusion: prior left atrial ablation; cardiac implantable electronic device; reduced left ventricular ejection fraction; GFR <30%; age <18 years; long-standing persistent atrial fibrillation; pregnancy or lactation; BMI >35%; left atrial diameter >55 mm.